See the DrugPatentWatch profile for keytruda

Keytruda, a cancer treatment drug manufactured by Merck & Co., is derived from a type of immunotherapy known as PD-1 inhibitors. The drug's patent is held by Merck & Co., which has been granted several patents protecting Keytruda's composition, method of use, and manufacturing processes [1].

Merck & Co.'s patent portfolio for Keytruda includes patents that extend until 2028 and 2036 [2]. These patents cover various aspects of Keytruda, including its use in treating specific types of cancer, such as non-small cell lung cancer, melanoma, and head and neck squamous cell carcinoma [1].

According to DrugPatentWatch.com, Keytruda has several patents that have already expired, and some patents are set to expire in the coming years [3]. However, Merck & Co. has filed for and been granted additional patents that extend Keytruda's patent protection beyond the expiration of the initial patents [1].

In summary, Merck & Co. is the patent holder of Keytruda, with several patents protecting the drug's composition, method of use, and manufacturing processes. While some patents have expired, Merck & Co. has filed and been granted additional patents that extend Keytruda's patent protection until 2036 [1][2][3].

Sources:

[1] "Keytruda (pembrolizumab)". Drugs.com. <https://www.drugs.com/ppa/keytruda.html>.

[2] "Merck's Keytruda Patent Portfolio". Goodwin Biotechnology. <https://www.goodwinbiotech.com/mercks-keytruda-patent-portfolio/>.

[3] "Keytruda (pembrolizumab)". DrugPatentWatch.com. <https://www.patentdocs.org/keytruda-pembrolizumab/>.